+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antifungal Drugs Market by Drug Type, Route Of Administration, Dosage Form, Therapeutic Application, Distribution Channel, End User - Global Forecast to 2030- Product Image
Antifungal Drugs Market by Drug Type, Route Of Administration, Dosage Form, Therapeutic Application, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Antifungal Drugs Market by Drug Type, Route Of Administration, Dosage Form, Therapeutic Application, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337228
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antifungal Drugs Market grew from USD 15.80 billion in 2024 to USD 16.79 billion in 2025. It is expected to continue growing at a CAGR of 6.22%, reaching USD 22.70 billion by 2030.

Overview of the Evolving Antifungal Drugs Landscape

The global antifungal drugs arena has entered a pivotal phase characterized by heightened clinical demand, evolving resistance patterns, and accelerating innovation. Decision-makers across biotechnology firms, pharmaceutical manufacturers, and healthcare providers are seeking nuanced intelligence to navigate this complex ecosystem. The rising prevalence of invasive fungal infections, fueled by immunocompromised patient populations and expanding hospital procedures, underscores the urgency for next-generation therapies. As treatment paradigms shift from broad-spectrum agents to targeted mechanisms, stakeholders must assimilate granular insights on pipeline developments, regulatory trajectories, and commercialization strategies to maintain competitive advantage and optimize patient outcomes.

In this context, the imperative for a comprehensive executive summary becomes apparent. It distills multifaceted market dynamics into actionable intelligence, bridging the gap between strategic vision and operational execution. By synthesizing macroeconomic drivers, regulatory shifts, and technological breakthroughs, this overview equips industry leaders with the clarity needed to prioritize investments, anticipate supply chain disruptions, and foster collaborations that accelerate time to market.

Emerging Trends Redefining Antifungal Therapies

Breakthroughs in molecular biology and pharmacology are catalyzing a renaissance in antifungal drug development. Echinocandins, second-generation triazoles, and innovative lipid formulations are rapidly reshaping therapeutic algorithms, offering enhanced efficacy and safety profiles. Concurrently, diagnostic advancements such as nucleic acid amplification and lateral flow immunoassays enable earlier detection and targeted treatment, minimizing empirical therapy. Digital health platforms bolster adherence monitoring and telemedicine consultations, reinforcing patient-centric care models and optimizing resource allocation.

Simultaneously, the threat of antifungal resistance continues to mount, driven by prolonged prophylactic use and widespread agricultural fungicide application. Regulatory agencies are responding with expedited review pathways and adaptive licensing frameworks to incentivize novel therapeutic classes. In parallel, personalized medicine approaches, leveraging pharmacogenomics and biomarker-driven stratification, promise to refine dosing paradigms and reduce off-target effects. These transformative shifts demand that industry participants remain agile, forging cross-sector partnerships and rethinking traditional R&D pathways to keep pace with an era of unprecedented therapeutic potential.

Assessing the Ripple Effects of New US Tariffs in 2025

The introduction of revised United States tariffs in 2025 has generated significant strategic recalibrations across the antifungal landscape. Import duties on active pharmaceutical ingredients and finished formulations have incrementally increased production costs, compelling manufacturers to revisit sourcing strategies. Many suppliers are accelerating localization of raw material procurement and considering nearshoring opportunities to mitigate margin erosion and ensure supply chain resilience.

These tariff adjustments also reverberate through pricing and reimbursement negotiations, especially since healthcare payers are intensely focused on cost containment. Companies are leveraging advanced cost-modeling tools to simulate patient access scenarios under fluctuating price ceilings. Additionally, contractual engagements with contract development and manufacturing organizations are under renegotiation, with an emphasis on cost-sharing mechanisms that align incentives and safeguard supply continuity. Ultimately, the 2025 tariff environment underscores the importance of adaptive manufacturing footprints and integrated supply chain governance in sustaining competitive positioning.

Unveiling Critical Segmentation Patterns in Antifungal Markets

Insight into market segmentation reveals that drug type analysis distinguishes systemic therapies, delivered via intravenous or oral administration, from topical formulations encompassing creams, ointments, and powders. This dual framework reflects the divergent clinical pathways and cost structures associated with systemic versus localized interventions. Route of administration further refines this analysis, spotlighting the strategic interplay between intravenous regimens, oral dosing convenience, and topical accessibility, each channel offering unique patient adherence and clinical efficacy considerations.

Dosage form segmentation adds another layer of depth, with capsules, tablets, and suspensions representing the backbone of oral pharmacotherapy, while creams, ointments, and powders address the specific needs of dermatological infections. Therapeutic application analysis encompasses aspergillosis in its chronic and invasive manifestations, candidiasis including oropharyngeal, systemic, and vulvovaginal forms, cryptococcosis, and dermatophytosis subdivided into tinea corporis and tinea pedis. Each disease indication carries distinct epidemiological trends, diagnostic challenges, and pricing dynamics that inform pipeline prioritization and commercial strategy.

Distribution channel evaluation spans drug stores, hospital pharmacies operating in both private and public sectors, online channels serving business-to-business and consumer-direct models, and retail pharmacies structured as chain outlets or independent establishments. This network diversity drives variation in procurement cycles, margin structures, and promotional tactics. Finally, end user segmentation highlights clinical delivery points-from dermatology and general clinics to homecare environments and hospitals classified by private or public ownership-underscoring the criticality of tailored value propositions and channel-specific engagement strategies.

Regional Dynamics Shaping Antifungal Demand Worldwide

Regional analysis exposes divergent growth trajectories shaped by regulatory frameworks, healthcare infrastructure, and pathogen prevalence. In the Americas, the market is propelled by extensive clinical research networks, robust reimbursement systems, and heightened awareness of invasive fungal diseases among immunocompromised patients. Strategic alliances between multinational biopharmaceutical firms and local distributors optimize market penetration and drive adoption of premium-priced novel agents.

The Europe, Middle East & Africa region exhibits heterogeneity in regulatory harmonization and healthcare expenditure. Western European markets demonstrate strong uptake of advanced antifungal therapies under comprehensive insurance schemes, while emerging markets in Eastern Europe and select Middle Eastern territories are marked by budgetary constraints and slower generics penetration. African nations contend with infrastructural limitations but benefit from donor-funded programs and capacity-building initiatives that enhance diagnostic and treatment access.

Asia-Pacific is characterized by a rapidly expanding patient pool, driven by rising incidence of diabetes and increased surgical procedures. Regulatory reforms in leading markets such as Japan, China, and Australia are streamlining approval processes and fostering local manufacturing. Meanwhile, Southeast Asian and South Asian countries are intensifying surveillance efforts to combat antifungal resistance, presenting opportunities for companies offering diagnostic-linked therapeutic solutions.

Spotlight on Industry Leaders and Their Strategic Moves

Leading pharmaceutical and biotechnology companies are vying for superiority through differentiated pipelines, strategic collaborations, and M&A activity. Key global players have fortified their R&D portfolios with late-stage clinical programs targeting refractory fungal infections and leveraging novel mechanisms of action. Some firms are forging partnerships with specialty biotech ventures to co-develop lipid-based and nanoparticle formulations that promise improved tissue penetration and reduced toxicity.

Several companies are also investing in digital health synergies, embedding adherence monitoring tools and real-world evidence platforms into their commercial offerings. Concurrently, mid-sized innovators are carving niche positions by focusing on orphan indications and pediatric formulations, effectively complementing blockbuster franchises. Cost-efficient production technologies and contract manufacturing relations are enabling both established leaders and agile newcomers to scale supply swiftly while maintaining stringent quality standards and regulatory compliance.

Strategic Imperatives for Maximizing Market Opportunities

Industry leadership demands a proactive stance in anticipating clinical and regulatory shifts. Executives should prioritize investment in R&D initiatives that harness precision medicine, including biomarker-guided trial designs and adaptive protocol frameworks. By integrating diagnostic co-development into therapeutic pipelines, companies can demonstrate differentiated value to payers and accelerate market access.

Furthermore, establishing regional manufacturing hubs and flexible supply chain networks will mitigate tariff exposure and bolster responsiveness to demand fluctuations. Collaboration with third-party logistics providers and strategic raw material suppliers will ensure continuity and cost predictability. A focused M&A strategy targeting high-value pipeline assets or complementing existing portfolios can rapidly augment therapeutic breadth and market reach.

Finally, cultivating digital ecosystems that support patient adherence, remote monitoring, and real-world data capture will differentiate offerings and strengthen payer negotiations. Building comprehensive value dossiers, underpinned by pharmacoeconomic modeling and health-outcome data, will be critical in securing formulary placements and reimbursement favorable terms.

Rigorous Research Framework Underpinning Our Analysis

Our methodology integrates a rigorous blend of primary and secondary research to ensure comprehensive coverage and robust validation. Primary research involved interviews with senior executives, clinical investigators, and regulatory authorities, yielding qualitative insights into strategy, market access, and unmet clinical needs. Secondary research encompassed an extensive review of scientific publications, patent filings, regulatory submissions, and corporate disclosures to triangulate quantitative data and benchmark recent market developments.

Data analysis leveraged advanced analytics tools, enabling scenario modeling and sensitivity analyses across pricing, reimbursement, and adoption curves. Cross-validation procedures were applied at each stage to reconcile discrepancies and confirm data integrity. The research framework was further refined through expert panel reviews and targeted surveys, ensuring that our findings reflect real-world dynamics and forward-looking perspectives.

Synthesizing Insights for Future Antifungal Strategies

The antifungal drugs sector stands at an inflection point, driven by innovation in molecular targets, evolving resistance landscapes, and shifting regulatory priorities. By synthesizing transformative trends, tariff impacts, segmentation granularity, regional dynamics, and competitive strategies, this executive summary equips leaders with a strategic compass for charting the path forward. The insights presented herein lay the groundwork for informed decision-making, enabling organizations to optimize clinical development, commercial deployment, and long-term value creation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Type
    • Systemic
      • Intravenous
      • Oral
    • Topical
      • Cream
      • Ointment
      • Powder
  • Route Of Administration
    • Intravenous
    • Oral
    • Topical
  • Dosage Form
    • Capsule
    • Cream
    • Ointment
    • Powder
    • Suspension
    • Tablet
  • Therapeutic Application
    • Aspergillosis
      • Chronic
      • Invasive
    • Candidiasis
      • Oropharyngeal
      • Systemic
      • Vulvovaginal
    • Cryptococcosis
    • Dermatophytosis
      • Tinea Corporis
      • Tinea Pedis
  • Distribution Channel
    • Drug Store
    • Hospital Pharmacy
      • Private
      • Public
    • Online Pharmacy
      • B2B
      • B2C
    • Retail Pharmacy
      • Chain
      • Independent
  • End User
    • Clinics
      • Dermatology
      • General
    • Homecare
    • Hospitals
      • Private
      • Public
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Gilead Sciences, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antifungal Drugs Market, by Drug Type
8.1. Introduction
8.2. Systemic
8.2.1. Intravenous
8.2.2. Oral
8.3. Topical
8.3.1. Cream
8.3.2. Ointment
8.3.3. Powder
9. Antifungal Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
10. Antifungal Drugs Market, by Dosage Form
10.1. Introduction
10.2. Capsule
10.3. Cream
10.4. Ointment
10.5. Powder
10.6. Suspension
10.7. Tablet
11. Antifungal Drugs Market, by Therapeutic Application
11.1. Introduction
11.2. Aspergillosis
11.2.1. Chronic
11.2.2. Invasive
11.3. Candidiasis
11.3.1. Oropharyngeal
11.3.2. Systemic
11.3.3. Vulvovaginal
11.4. Cryptococcosis
11.5. Dermatophytosis
11.5.1. Tinea Corporis
11.5.2. Tinea Pedis
12. Antifungal Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Drug Store
12.3. Hospital Pharmacy
12.3.1. Private
12.3.2. Public
12.4. Online Pharmacy
12.4.1. B2B
12.4.2. B2C
12.5. Retail Pharmacy
12.5.1. Chain
12.5.2. Independent
13. Antifungal Drugs Market, by End User
13.1. Introduction
13.2. Clinics
13.2.1. Dermatology
13.2.2. General
13.3. Homecare
13.4. Hospitals
13.4.1. Private
13.4.2. Public
14. Americas Antifungal Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antifungal Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antifungal Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Merck & Co., Inc.
17.3.3. Astellas Pharma Inc.
17.3.4. F. Hoffmann-La Roche Ltd.
17.3.5. Johnson & Johnson
17.3.6. Novartis AG
17.3.7. Bristol-Myers Squibb Company
17.3.8. Bayer AG
17.3.9. Teva Pharmaceutical Industries Ltd.
17.3.10. Gilead Sciences, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIFUNGAL DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIFUNGAL DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIFUNGAL DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTIFUNGAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTIFUNGAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIFUNGAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OROPHARYNGEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY VULVOVAGINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA CORPORIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA PEDIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY B2B, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY B2C, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CHAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY GENERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 100. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 102. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 103. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 105. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 107. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 108. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 109. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 111. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 112. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 113. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 115. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 118. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 121. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 128. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 198. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 199. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 200. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 202. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 204. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 205. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 206. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 208. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 209. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 210. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 212. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 213. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 215. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 216. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 218. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 220. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 221. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 222. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 224. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 225. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 226. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 228. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 245. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 246. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 247. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 248. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 250. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 252. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 253. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 254. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 256. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 257. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 260. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 261. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 263. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 264. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 266. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 268. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 269. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 270. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 272. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 273. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 274. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 276. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 324. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 325. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 326. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 327. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 328. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 329. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 330. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 331. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 332. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 333. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 334. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 336. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 337. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 338. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 339. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 340. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 341. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 342. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 343. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 344. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 345. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 346. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 347. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2030 (USD MILLION)
TABLE 348. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2030 (USD MILLION)
TABLE 349. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2030 (USD MILLION)
TABLE 350. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY DIS

Companies Mentioned

The companies profiled in this Antifungal Drugs market report include:
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Gilead Sciences, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.7 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antifungal Drugs - Global Strategic Business Report - Product Image

Antifungal Drugs - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Antifungal Drugs Market Report by Drug Class, Indication, and Region 2024-2032 - Product Image

Antifungal Drugs Market Report by Drug Class, Indication, and Region 2024-2032

  • Report
  • 147 Pages
  • Global
From
Antifungals Market Report 2025 - Product Image

Antifungals Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Anti-Infective Agents Market Size, Share & Trends Analysis Report By Type (Antibacterial, Antiviral, Antifungal & Antiparasitic), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Anti-Infective Agents Market Size, Share & Trends Analysis Report By Type (Antibacterial, Antiviral, Antifungal & Antiparasitic), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • Global
From
Antifungal Coating Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Antifungal Coating Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 78 Pages
  • Global
From

About the Antifungal Drug Market

The Antifungal Drug market is a subset of the larger Infectious Diseases Drugs market. Antifungal drugs are used to treat fungal infections, which can range from mild to life-threatening. These drugs work by either killing the fungus or preventing its growth. Common antifungal drugs include azoles, polyenes, and echinocandins. Azoles are the most commonly prescribed antifungal drugs, and are used to treat a wide range of fungal infections. Polyenes are used to treat more serious fungal infections, while echinocandins are used to treat severe fungal infections. The Antifungal Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, GlaxoSmithKline, and AstraZeneca. Other companies in the market include Bayer, Sanofi, Allergan, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.